Kynurenine monooxygenase (KMO) inhibition as a novel therapy for endometriosis: proof-of-concept

Mole, Damian (Principal Investigator)
Horne, Andrew (Co-investigator)
Saunders, Philippa (Co-investigator)

Deanery of Clinical Sciences

Status	Finished
Effective start/end date	1/02/21 → 30/06/22

Funding

Medical Research Council: £80,812.61
Medical Research Council: £12,933.88

1 Article

Kynurenine monooxygenase blockade reduces endometriosis-like lesions, improves visceral hyperalgesia, and rescues mice from a negative behavioural phenotype in experimental endometriosis.
Higgins, B., Simitsidellis, I., Zheng, X., Collins, F., Homer, N. Z. M., Denham, S. G., Simpson, J. P., Millar, M., Boswell, L., Lee, H. Y., Kim, Y. G., Park, K. H., Park, L. C., Sweeney, P. J., Feraille, G., Taddei, A., Chagras, D., Alvaraz, T., Webster, S. P. & Horne, A. & 2 others, Saunders, P. T. K. & Mole, D. J., 2 Aug 2024, In: eLIFE.
Research output: Contribution to journal › Article › peer-review

Open Access
File